Allergopharma GmbH & Co. KG clinical trials
Acquired by Dermapharm Holding SE, Mar 31, 2020 · source ↗
The registry lists 23 studies whose lead sponsor is Allergopharma GmbH & Co. KG. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2025.
- 23studies on the registry
- 1open to participants now
Before and after it joined Dermapharm Holding SE
- First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- 22
- First submitted after Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Allergopharma GmbH & Co. KG’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- Bee Venoms1 in phase 30 open · 1
All 23 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 507
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 10 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- Allergopharma GmbH & Co. KG23 studies
Something wrong with this grouping? Tell us on the Dermapharm Holding SE page.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. All Dermapharm Holding SE studies →
- Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust MitesNot yet recruitingNCT07096440
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted after Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical TrialsTerminatedNCT02297490Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in ChildrenCompletedNCT00841256Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial AsthmaCompletedNCT00263640Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled AsthmaCompletedNCT01353755Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen AllergensCompletedNCT00263627Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic RhinoconjunctivitisCompletedNCT00263601Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen MixtureCompletedNCT00264459Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal RhinoconjunctivitisCompletedNCT01490411Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled AsthmaCompletedNCT00671268Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Efficacy and Safety From a High-dosed Sublingual Grass Pollen PreparationCompletedNCT00623701Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic DerivativeCompletedNCT00841516Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) AllergensCompletedNCT00666341Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Efficacy and Safety From a Recombinant Folding Variant of Bet v 1CompletedNCT00554983Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.CompletedNCT00665483Phase 4
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic RhinoconjunctivitisCompletedNCT00309062Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Efficacy and Safety of a Purified Standardised Wasp Venom PreparationCompletedNCT00263926Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Open Label Safety Study of a Birch Pollen Allergen ExtractCompletedNCT00818181Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic RhinoconjunctivitisCompletedNCT00309036Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FVCompletedNCT00266526Phase 2
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Efficacy and Safety of a Purified Standardised Bee Venom PreparationCompletedNCT00263952Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Multicenter Trial of Immunotherapy With House Dust Mite AllergoidCompletedNCT00540631Phase 3
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE
- Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic RhinoconjunctivitisCompletedNCT00263549Phase 4
Sponsor listed in the registry: Allergopharma GmbH & Co. KG · First submitted before Allergopharma GmbH & Co. KG became part of Dermapharm Holding SE